Recent News

• 11.25.2025 - Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
• 11.19.2025 - Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
• 11.06.2025 - Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
• 11.04.2025 - Viking Therapeutics to Participate at Upcoming Investor Conferences
• 10.29.2025 - Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
• 10.22.2025 - Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.21.2025 - Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
• 10.15.2025 - Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Recent Filings

• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 144 Report of proposed sale of securities
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 144 Report of proposed sale of securities
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 144 Report of proposed sale of securities
• 10.27.2025 - 144 Report of proposed sale of securities
• 10.23.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]